Medline ® Abstract for Reference 5
of 'Immunotherapy of non-small cell lung cancer with immune checkpoint inhibition'
Phase 3, Randomized Trial (CheckMate 057) of Nivolumab vs Docetaxel in Advanced Non-Squamous (Non-SQ) Non-Small Cell Lung Cancer (NSCLC): Subgroup Analyses and Patient-Reported Outcomes (PROs)
Horn L, Brahmer J, Reck M, Borghaei H, Spigel DR
European Cancer Conference. 2015;European Society of Medical Oncology(2015)